Pharm - Female Flashcards
Aromatase inhibitors for breast cancer
Anastrozole, Exemestane, Letrozole
SERDs and SERMs for breast cancer
Raloxifene, Tamoxifen, Toremifene, Fulvestrant
GnRH agonist for breast cancer
Goserelin
HER-2/neu antibodies for breast cancer
Pertuzumab, Trastuzumab, Ado-Trastuzumab, Emtasine
TKI for breast cancer
Lapatinib
mTOR inhibitor for breast cancer
Everolimus
Intervention strategies for premenopausal women
GnRH agonists, GnRH antagonists, surgical ablation, SERM, pure antigestrogen
Intervention strategies for postmenopausal women
aromatase inhibitors, SERM, receptor destabilizer
Fulvestrant MOA
inhibits receptor dimerization leading to increased turnover and disruption of nuclear localization
Fulvestrant AE
nausea, asthenia, pain, vasodilation, and HA
Tamoxifen BBW
endometrial hypertrophy, vaginal bleeding, endometrial cancer, thromboembolic disease (DVT or PE), stroke
Raloxifene BBW
Thromboembolic disease, stroke
Toremifene BBW
prolongs QT interval - avoid in preexisting condition and with 3A4 inhibitors; avoid with Hx of endometrial cancer/hyperplasia, thromboembolic disease
Anastrozole, Letrozole, Exemestane MOA
aromatase inhibitors; non-steroidal (reversible inhibition), steroidal (irreversible inhibitor)
Aromatase inhibitor AE
hot flashes, nausea, hair thinning; more arthralgia and diarrhea but fewer gynecologic symptoms than tamoxifen.
Pertuzumab AE
alopecia, loss of appetite, decreased LVEF, neutropenia, and leukopenia
Trastuzumab AE
peripheral edema, rash, weight gain, dizziness, URTIs, pharyngitis, fatigue, cardiomyopathy and HF, renal failure, hepatotoxicity, pneumonia and respiratory failure
Drugs used in combination with Pertuzumab and Trastuzumab
Taxanes
BBW for Pertuzumab
pregnancy
BBW for Trastuzumab
cardiomyopathy, infusion reactions, pregnancy, respiratory distress syndrome, respiratory insufficiency
BBW for Ado-Trastuzumab
Heart failure, Heptic disease, pregnancy, ventricular dysfunction
Lapatinib BBW
liver disease
Lapatinib AE
CYP3E4/5 interactions, GI issues, anemia, thrombocytopenia, hand-foot syndrome, interstitial lung disease/pneumonitis, QT prolongation
Goserelin AE
hypo-estrogenic effects; decreased bone density, osteopenia/osteoporosis
Everolimus BBW
risk of opportunistic infections - neoplasia; lymphoma/SCC
Everolimus AE
non-infectious pneumonitis, blood dyscrasias, hyperglycemia, hyperlipidemia, hypertriglyceridemia, elevated creatinine and LFTs
Treatment of triple negative Breast Cancer with lymph node positive
adjuvant anthracycline and Taxane-based chemotherapy
Standard Adjuvant chemotherapy regimens for breast cancer
cyclophosphamide/doxorubicin +/- taxol, fluorouracil, docetaxel; docetaxel/cyclophosphamide
Medroxyprogesterone MOA
used for endometrial cancer; binds to progestin receptors and block GnRH release
Medroxyprogesterone AE
amenorrhea, edema, anorexia, weakness
Megestrol MOA
used for endometrial cancer or breast cancer; suppresses pituitary LH release and enhances estrogen degradation, promoting differentiation/maintenance of endometrial tissue
Megestrol AE
weight gain, hot flashes, malaise, asthenia, lethargy, tumor flare and hypercalcemia in BC pts with bony metastases, thrombophlebitis, thrombo or pulm embolism
Increased risk due to HRT
coronary heart disease, invasive breast cancer, stroke, PE. gallbladder disease, dementia, urinary incontinence